Renowned MRI expert, Prof. Jim Wild, will discuss the clinical applications of 129Xe lung imaging with a focus on novel pulmonary therapies using hyperpolarized gas and proton lung MRI as markers.
2015 marked the first ever translation of hyperpolarized gas MRI to diagnostic clinical practice. Research at the University of Sheffield now continues with hyperpolarized 3He and 129Xe gas lung MRI and asthma, COPD, cystic fibrosis, interstitial lung disease, lung cancer and pulmonary hypertension.
In this Bruker webinar, Prof. Jim Wild, head of POLARIS (Pulmonary, Lung and Respiratory Imaging Sheffield) at the University of Sheffield will discuss methodology for hyperpolarized 129Xe MRI in humans including, polarizer physics, RF coils, pulse sequence design, and functional imaging methods to study microstructure, gas exchange, air flow. He will also shed light on regulatory aspects and overview of clinical applications in the lungs and other organs. Dr. Wild will share from his extensive knowledge on hyperpolarization lung imaging in humans and give insight into the novel pulmonary therapies using hyperpolarized gas and proton lung MRI as markers that his group is evaluating in collaboration with pharmaceutical companies.
Key Topics Include:
Pulmonary Imaging:
- Translation of hyperpolarized gas MRI to diagnostic clinical practice
- Novel pulmonary therapies
- Measuring and modelling lung physiology and microstructure
Hyperpolarization Imaging:
- RF coil engineering for 3He and 129Xe MRI
- Rapid acquisition methods – radial, compressed sensing, steady state free precession and parallel imaging
- Techniques for simultaneous imaging of 1H, 3He and 129Xe in the lungs
Presenters
Professor of Magnetic Resonance Physics
University of Sheffield
Production Partner
Bruker Corporation
